

B1 cont.
Sub
Entry
(b) ~~biologically functional [multimeric proteins]~~
immunoglobulin product encoded by said nucleotide sequences.

Please cancel claims 22-31 without prejudice or disclaimer.

Please amend claims 32-37 as follows.

In each of claims 32-37, please delete the phrase "claim 31" and replace it with the phrase --claim 21--. In other words, please amend all of claims 32-37 so that they now depend from claim 21 instead of claim 31.

Please amend claim 38 as follows.

B2 8 20. The plant of claim 21 wherein the [multimeric protein]
immunoglobulin product comprises a glycosylated immunoglobulin molecule free of sialic acid residues.

REMARKS

Claims 21 and 38 have been amended to define the invention with more clarity and particularity. Claims 1 and 22-31 have been cancelled without prejudice or disclaimer. Claims 21 and 32-37 remain before the Examiner. Applicants respectfully request reconsideration and reexamination of those claims in their presently amended form.

Rejections Under 35 U.S.C. § 112, First Paragraph

The Examiner has rejected claims 21-30 under the first paragraph of 35 U.S.C. § 112 as allegedly containing subject matter which does not describe in the specification in an enabling manner. In view of the amendment to claim 21 and the cancellation of claims 22-31, this rejection should no longer

B2